Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
1.
J Adv Res ; 55: 103-118, 2024 Jan.
Article in English | MEDLINE | ID: mdl-36871616

ABSTRACT

BACKGROUND: Cancer management faces multiple obstacles, including resistance to current therapeutic approaches. In the face of challenging microenvironments, cancer cells adapt metabolically to maintain their supply of energy and precursor molecules for biosynthesis and thus sustain rapid proliferation and tumor growth. Among the various metabolic adaptations observed in cancer cells, the altered glucose metabolism is the most widely studied. The aberrant glycolytic modification in cancer cells has been associated with rapid cell division, tumor growth, cancer progression, and drug resistance. The higher rates of glycolysis in cancer cells, as a hallmark of cancer progression, is modulated by the transcription factor hypoxia inducible factor 1 alpha (HIF-1α), a downstream target of the PI3K/Akt signaling, the most deregulated pathway in cancer. AIM OF REVIEW: We provide a detailed overview of current, primarily experimental, evidence on the potential effectiveness of flavonoids to combat aberrant glycolysis-induced resistance of cancer cells to conventional and targeted therapies. The manuscript focuses primarily on flavonoids reducing cancer resistance via affecting PI3K/Akt, HIF-1α (as the transcription factor critical for glucose metabolism of cancer cells that is regulated by PI3K/Akt pathway), and key glycolytic mediators downstream of PI3K/Akt/HIF-1α signaling (glucose transporters and key glycolytic enzymes). KEY SCIENTIFIC CONCEPTS OF REVIEW: The working hypothesis of the manuscript proposes HIF-1α - the transcription factor critical for glucose metabolism of cancer cells regulated by PI3K/Akt pathway as an attractive target for application of flavonoids to mitigate cancer resistance. Phytochemicals represent a source of promising substances for cancer management applicable to primary, secondary, and tertiary care. However, accurate patient stratification and individualized patient profiling represent crucial steps in the paradigm shift from reactive to predictive, preventive, and personalized medicine (PPPM / 3PM). The article is focused on targeting molecular patterns by natural substances and provides evidence-based recommendations for the 3PM relevant implementation.


Subject(s)
Neoplasms , Proto-Oncogene Proteins c-akt , Humans , Proto-Oncogene Proteins c-akt/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Flavonoids , Precision Medicine , Signal Transduction , Neoplasms/drug therapy , Neoplasms/metabolism , Transcription Factors , Glucose/metabolism , Tumor Microenvironment
2.
Pathogens ; 12(12)2023 Dec 07.
Article in English | MEDLINE | ID: mdl-38133305

ABSTRACT

Herpesviruses, a family of enveloped DNA viruses, pose significant threats to both humans and animals [...].

3.
Viruses ; 15(12)2023 11 29.
Article in English | MEDLINE | ID: mdl-38140581

ABSTRACT

The herpes simplex virus (HSV) is a double-stranded DNA human virus that causes persistent infections with recurrent outbreaks. HSV exists in two forms: HSV-1, responsible for oral herpes, and HSV-2, primarily causing genital herpes. Both types can lead to significant complications, including neurological issues. Conventional treatment, involving acyclovir and its derivatives, faces challenges due to drug resistance. This underscores the imperative for continual research and development of new drugs, with a particular emphasis on exploring the potential of natural antivirals. Flavonoids have demonstrated promise in combating various viruses, including those within the herpesvirus family. This review, delving into recent studies, reveals the intricate mechanisms by which flavonoids decode their antiviral capabilities against HSV. By disrupting key stages of the viral life cycle, such as attachment to host cells, entry, DNA replication, latency, and reactivation, flavonoids emerge as formidable contenders in the ongoing battle against HSV infections.


Subject(s)
Herpes Simplex , Herpesvirus 1, Human , Humans , Animals , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Flavonoids/pharmacology , Flavonoids/therapeutic use , Herpes Simplex/drug therapy , Herpesvirus 1, Human/physiology , Life Cycle Stages
4.
Int J Mol Sci ; 24(21)2023 Nov 02.
Article in English | MEDLINE | ID: mdl-37958882

ABSTRACT

The integration of molecular approaches in medicine allows for a more precise understanding of the mechanisms underlying infectious diseases, paving the way for targeted therapies, personalized medicine, and the development of new diagnostic tools [...].


Subject(s)
Communicable Diseases , Molecular Medicine , Humans , Precision Medicine , Communicable Diseases/diagnosis , Communicable Diseases/drug therapy
5.
Rev. esp. anestesiol. reanim ; 70(8): 438-446, Octubre 2023. tab, graf
Article in Spanish | IBECS | ID: ibc-225926

ABSTRACT

Antecedentes: Las cirugías laparoscópicas inducen dolores de hombro y abdominales significativos, que fluctúan entre 35 y 80% de los pacientes, a pesar de sus ventajas. La causa del dolor posterior a la laparoscopia no se comprende plenamente, suponiéndose que es multifactorial y posiblemente un tipo de dolor referido. Objetivo del estudio Evaluar el efecto de los diferentes modelos analgésicos en el dolor posterior a la laparoscopia y en las modulaciones del marcador inflamatorio. Métodos Se asignó aleatoriamente a los pacientes programados para colecistectomía laparoscópica electiva, para recibir una infiltración local en la fosa hepática y el área subdiafragmática derecha con uno de los cuatro tipos de mezcla analgésica de fármacos siguientes: grupo 1 (G1) con 20 mL de bupivacaína al 0,25%; grupo 2 (G2) con 20 mL de bupivacaína al 0,25% + 3 mg de sulfato de morfina; grupo 3 (G3) con 20 mL de bupivacaína al 0,25% + 3 mg de sulfato de morfina + 200 mcg/kg de ketamina; y grupo 4 (G4) con 20 mL de solución salina isotónica como grupo control. Resultados El G3 demostró unos niveles significativamente bajos en la escala de calificación numérica oral del dolor de hombro y marcadores inflamatorios, en contraste con los tres grupos restantes. Los altos niveles de marcadores inflamatorios, estadísticamente significativos, fueron registrados en el grupo control en la comparación entre los grupos de estudio. No se documentaron efectos secundarios ni complicaciones en los cuatro grupos. Conclusión La adición de ketamina y morfina a bupivacaína para insuflado hepático y subdiafragmático produjo buena analgesia y redujo los niveles de los marcadores inflamatorios tras colecistectomía laparoscópica. (AU)


Background: Despite the advantages of laparoscopic surgeries, its induced shoulder and abdominal pain are significant, ranging from 35% to 80%. The cause of post laparoscopic pain is not fully understood and supposed to be multifactorial and possibly referred to as pain. Aim of the study Evaluate the effect of different analgesic models on post-laparoscopic pain and inflammatory markers modulation. Methods Patients scheduled for elective laparoscopic cholecystectomy randomLy assigned to receive local infiltration of the hepatic and right subdiaphragmatic fossae with one of four types of the analgesic mixture of drugs:-Group-1 (G1): 20 mL of (bupivacaine 0.25%) Group-2 (G2): 20 mL of (bupivacaine 0.25% + 3 mg of Morphine sulphate) Group-3 (G3): 20 mL of (bupivacaine 0.25% + 3 mg of Morphine sulphate + 200 microgram/kg ketamine). Group-4 (G4): 20 mL of isotonic saline as the control group. Results Group 3 demonstrated significant low VNRS of shoulder pain and significantly low levels of inflammatory marker compared with the other three groups. Highest statistically significant levels of inflammatory markers recorded in the control group among the study groups. No side effects or complications documented in the four study groups. Conclusión The addition of Ketamine and Morphine to the Bupivacaine for hepatic and subdiaphragmatic insufflation produced good analgesia and reduced the levels of inflammatory markers after Laparoscopic cholecystectomy. (AU)


Subject(s)
Humans , Cholecystectomy, Laparoscopic/instrumentation , Cholecystectomy, Laparoscopic/methods , Analgesics/administration & dosage , Analgesics/adverse effects , Analgesics/pharmacology , Analgesics/therapeutic use , Surgical Procedures, Operative/methods , Surgical Procedures, Operative/rehabilitation
6.
Rev Esp Anestesiol Reanim (Engl Ed) ; 70(8): 438-446, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37678451

ABSTRACT

BACKGROUND: Despite its advantages, laparoscopic surgery causes significant shoulder and abdominal pain in 35%-80% of patients. The cause of post-laparoscopy pain is not fully understood, but it is assumed to be a multifactorial referred pain. AIM OF THE STUDY: To evaluate the effect of different analgesia techniques on post-laparoscopic pain and inflammatory markers. METHODS: Patients scheduled for elective laparoscopic cholecystectomy were randomly assigned to receive local hepatic and right subdiaphragmatic infiltration of one of the 4 study drug combinations: Group 1 (G1) received 20 ml bupivacaine 0.25%; Group 2 (G2) received 20 ml bupivacaine 0.25% +3 mg morphine sulphate; Group 3 (G3) received 20 ml bupivacaine 0.25% + 3 mg morphine sulphate +200 µg/kg ketamine; and Group 4 (G4) received 20 ml isotonic saline as the control group. RESULTS: In G3, both shoulder pain on the verbal numerical rating scale and inflammatory marker levels were lower compared with the other groups. The highest levels of inflammatory markers were observed in the control group; this difference was statistically significant. No side effects or complications were observed in the study groups. CONCLUSION: The addition of ketamine and morphine to bupivacaine for hepatic and subdiaphragmatic infiltration produced good analgesia and reduced inflammatory marker levels after laparoscopic cholecystectomy.

7.
Front Pharmacol ; 14: 1160068, 2023.
Article in English | MEDLINE | ID: mdl-37089930

ABSTRACT

Significant limitations of the reactive medical approach in breast cancer management are clearly reflected by alarming statistics recorded worldwide. According to the WHO updates, breast malignancies become the leading cancer type. Further, the portion of premenopausal breast cancer cases is permanently increasing and demonstrates particularly aggressive patterns and poor outcomes exemplified by young patients with triple-negative breast cancer that lacks targeted therapy. Accumulating studies suggest the crucial role of stem cells in tumour biology, high metastatic activity, and therapy resistance of aggressive breast cancer. Therefore, targeting breast cancer stem cells is a promising treatment approach in secondary and tertiary breast cancer care. To this end, naturally occurring substances demonstrate high potential to target cancer stem cells which, however, require in-depth analysis to identify effective anti-cancer agents for cost-effective breast cancer management. The current article highlights the properties of flavonoids particularly relevant for targeting breast cancer stem cells to mitigate therapy resistance. The proposed approach is conformed with the principles of 3P medicine by applying predictive diagnostics, patient stratification and treatments tailored to the individualised patient profile. Expected impacts are very high, namely, to overcome limitations of reactive medical services improving individual outcomes and the healthcare economy in breast cancer management. Relevant clinical applications are exemplified in the paper.

8.
Front Pharmacol ; 14: 1121950, 2023.
Article in English | MEDLINE | ID: mdl-37033601

ABSTRACT

Cancer causes many deaths worldwide each year, especially due to tumor heterogeneity leading to disease progression and treatment failure. Targeted treatment of heterogeneous population of cells - cancer stem cells is still an issue in protecting affected individuals against associated multidrug resistance and disease progression. Nanotherapeutic agents have the potential to go beyond state-of-the-art approaches in overall cancer management. Specially assembled nanoparticles act as carriers for targeted drug delivery. Several nanodrugs have already been approved by the US Food and Drug Administration (FDA) for treating different cancer types. Phytochemicals isolated from plants demonstrate considerable potential for nanomedical applications in oncology thanks to their antioxidant, anti-inflammatory, anti-proliferative, and other health benefits. Phytochemical-based NPs can enhance anticancer therapeutic effects, improve cellular uptake of therapeutic agents, and mitigate the side effects of toxic anticancer treatments. Per evidence, phytochemical-based NPs can specifically target CSCs decreasing risks of tumor relapse and metastatic disease manifestation. Therefore, this review focuses on current outlook of phytochemical-based NPs and their potential targeting CSCs in cancer research studies and their consideration in the framework of predictive, preventive, and personalized medicine (3PM).

9.
Int J Mol Sci ; 23(22)2022 Nov 11.
Article in English | MEDLINE | ID: mdl-36430369

ABSTRACT

Herpesviruses are one of the most contagious DNA viruses that threaten human health, causing severe diseases, including, but not limited to, certain types of cancer and neurological complications. The overuse and misuse of anti-herpesvirus drugs are key factors leading to drug resistance. Therefore, targeting human herpesviruses with natural products is an attractive form of therapy, as it might improve treatment efficacy in therapy-resistant herpesviruses. Plant polyphenols are major players in the health arena as they possess diverse bioactivities. Hence, in this article, we comprehensively summarize the recent advances that have been attained in employing plant non-flavonoid polyphenols, such as phenolic acids, tannins and their derivatives, stilbenes and their derivatives, lignans, neolignans, xanthones, anthraquinones and their derivatives, curcuminoids, coumarins, furanocoumarins, and other polyphenols (phloroglucinol) as promising anti-herpesvirus drugs against various types of herpesvirus such as alpha-herpesviruses (herpes simplex virus type 1 and 2 and varicella-zoster virus), beta-herpesviruses (human cytomegalovirus), and gamma-herpesviruses (Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus). The molecular mechanisms of non-flavonoid polyphenols against the reviewed herpesviruses are also documented.


Subject(s)
Epstein-Barr Virus Infections , Herpesviridae Infections , Humans , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Herpesviridae Infections/drug therapy , Polyphenols/pharmacology , Polyphenols/therapeutic use , Epstein-Barr Virus Infections/drug therapy , Herpesvirus 4, Human , Herpesvirus 3, Human
11.
Compr Rev Food Sci Food Saf ; 21(5): 4422-4446, 2022 09.
Article in English | MEDLINE | ID: mdl-35904246

ABSTRACT

The growing interest in foods that can be beneficial to human health is bringing into focus some products that have been used locally for centuries but have recently gained worldwide attention. One of these foods is pumpkin seed oil, which has been used in culinary and traditional medicine, but recent data also show its use in the pharmaceutical and cosmetic industries. In addition, some sources refer to it as a potential functional food, mainly because it is obtained from pumpkin seeds, which contain many functional components. However, the production process of the oil may affect the content of these components and consequently the biological activity of the oil. In this review, we have focused on summarizing scientific data that explore the potential of pumpkin seed oil as a functional food ingredient. We provide a comprehensive overview of pumpkin seed oil chemical composition, phytochemical content, biological activity, and safety, as well as the overview of production processes and contemporary use. The main phytochemicals in pumpkin seed oil with health-related properties are polyphenols, phytoestrogens, and fatty acids, but carotenoids, squalene, tocopherols, and minerals may also contribute to health benefits. Most studies have been conducted in vitro and support the claim that pumpkin seed oil has antioxidant and antimicrobial activities. Clinical studies have shown that pumpkin seed oil may be beneficial in the treatment of cardiovascular problems of menopausal women and ailments associated with imbalance of sex hormones.


Subject(s)
Anti-Infective Agents , Cucurbita , Food Ingredients , Antioxidants/pharmacology , Carotenoids , Cucurbita/chemistry , Fatty Acids/chemistry , Female , Functional Food , Humans , Pharmaceutical Preparations , Phytochemicals , Phytoestrogens , Plant Oils/chemistry , Plant Oils/pharmacology , Polyphenols , Squalene , Tocopherols
12.
Plants (Basel) ; 11(10)2022 May 23.
Article in English | MEDLINE | ID: mdl-35631806

ABSTRACT

Ginkgo (Ginkgo biloba L.) is one of the most distinctive plants, characterized by excellent resistance to various environmental conditions. It is used as an ornamental plant and is recognized as a medicinal plant in both traditional and Western medicine. Its bioactive potential is associated with the presence of flavonoids and terpene trilactones, but many other compounds may also have synergistic effects. Flavonoid dimers-biflavonoids-are important constituents of ginkgophytopharmaceuticals. Currently, the presence of 13 biflavonoids has been reported in ginkgo, of which amentoflavone, bilobetin, sciadopitysin, ginkgetin and isoginkgetin are the most common. Their role in plants remains unknown, but their bioactivity and potential role in the management of human health are better investigated. In this review, we have provided an overview of the chemistry, diversity and biological factors that influence the presence of biflavonoids in ginkgo, as well as their bioactive and health-related properties. We have focused on their antioxidant, anticancer, antiviral, antibacterial, antifungal and anti-inflammatory activities as well as their potential role in the treatment of cardiovascular, metabolic and neurodegenerative diseases. We also highlighted their potential toxicity and pointed out further research directions.

13.
Viruses ; 14(3)2022 03 13.
Article in English | MEDLINE | ID: mdl-35336999

ABSTRACT

Human herpesviruses (HHVs) are large DNA viruses with highly infectious characteristics. HHVs can induce lytic and latent infections in their host, and most of these viruses are neurotropic, with the capacity to generate severe and chronic neurological diseases of the peripheral nervous system (PNS) and central nervous system (CNS). Treatment of HHV infections based on strategies that include natural products-derived drugs is one of the most rapidly developing fields of modern medicine. Therefore, in this paper, we lend insights into the recent advances that have been achieved during the past five years in utilizing flavonoids as promising natural drugs for the treatment of HHVs infections of the nervous system such as alpha-herpesviruses (herpes simplex virus type 1, type 2, and varicella-zoster virus), beta-herpesviruses (human cytomegalovirus), and gamma-herpesviruses (Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus). The neurological complications associated with infections induced by the reviewed herpesviruses are emphasized. Additionally, this work covers all possible mechanisms and pathways by which flavonoids induce promising therapeutic actions against the above-mentioned herpesviruses.


Subject(s)
Epstein-Barr Virus Infections , Herpesviridae Infections , Herpesvirus 1, Human , Central Nervous System , Flavonoids/pharmacology , Flavonoids/therapeutic use , Herpesviridae Infections/drug therapy , Herpesvirus 1, Human/genetics , Herpesvirus 3, Human/genetics , Herpesvirus 4, Human/genetics , Humans
14.
Viruses ; 14(2)2022 01 27.
Article in English | MEDLINE | ID: mdl-35215856

ABSTRACT

Infection with certain types of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) viruses, known as tumor viruses or oncogenic viruses, can lead to cancer [...].


Subject(s)
Neoplasms/virology , Oncogenic Viruses , Tumor Virus Infections/virology , Animals , Host-Pathogen Interactions , Humans , Neoplasms/therapy , Neoplasms/veterinary , Tumor Virus Infections/therapy , Tumor Virus Infections/veterinary
15.
Int J Mol Sci ; 24(1)2022 Dec 23.
Article in English | MEDLINE | ID: mdl-36613688

ABSTRACT

Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) are cancer-causing viruses that belong to human gamma-herpesviruses. They are DNA viruses known to establish lifelong infections in humans, with the ability to develop various types of cancer. Drug resistance remains the main barrier to achieving effective therapies for viral infections and cancer. Thus, new medications with dual antiviral and anticancer actions are highly needed. Flavonoids are secondary metabolites biosynthesized by plants with diverse therapeutic effects on human health. In this review, we feature the potential role of flavonoids (flavones, protoflavones, isoflavones, flavanones, flavonols, dihydroflavonols, catechins, chalcones, anthocyanins, and other flavonoid-type compounds) in controlling gamma-herpesvirus-associated cancers by blocking EBV and KSHV infections and inhibiting the formation and growth of the correlated tumors, such as nasopharyngeal carcinoma, Burkitt's lymphoma, gastric cancer, extranodal NK/T-cell lymphoma, squamous cell carcinoma, Kaposi sarcoma, and primary effusion lymphoma. The underlying mechanisms via targeting EBV and KSHV life cycles and carcinogenesis are highlighted. Moreover, the effective concentrations or doses are emphasized.


Subject(s)
Epstein-Barr Virus Infections , Herpesviridae , Herpesvirus 8, Human , Neoplasms , Sarcoma, Kaposi , Humans , Herpesvirus 4, Human/genetics , Herpesvirus 8, Human/genetics , Epstein-Barr Virus Infections/drug therapy , Flavonoids/pharmacology , Flavonoids/therapeutic use , Anthocyanins , Neoplasms/drug therapy , Sarcoma, Kaposi/pathology , Carcinogenesis
16.
EPMA J ; 12(3): 325-347, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34367380

ABSTRACT

The risks related to the COVID-19 are multi-faceted including but by far not restricted to the following: direct health risks by poorly understood effects of COVID-19 infection, overloaded capacities of healthcare units, restricted and slowed down care of patients with non-communicable disorders such as cancer, neurologic and cardiovascular pathologies, among others; social risks-restricted and broken social contacts, isolation, professional disruption, explosion of aggression in the society, violence in the familial environment; mental risks-loneliness, helplessness, defenceless, depressions; and economic risks-slowed down industrial productivity, broken delivery chains, unemployment, bankrupted SMEs, inflation, decreased capacity of the state to perform socially important programs and to support socio-economically weak subgroups in the population. Directly or indirectly, the above listed risks will get reflected in a healthcare occupation and workload which is a tremendous long-term challenge for the healthcare capacity and robustness. The article does not pretend to provide solutions for all kind of health risks. However, it aims to present the scientific evidence of great clinical utility for primary, secondary, and tertiary care to protect affected individuals in a cost-effective manner. To this end, due to pronounced antimicrobial, antioxidant, anti-inflammatory, and antiviral properties, naturally occurring plant substances are capable to protect affected individuals against COVID-19-associated life-threatening complications such as lung damage. Furthermore, they can be highly effective, if being applied to secondary and tertiary care of noncommunicable diseases under pandemic condition. Thus, the stratification of patients evaluating specific health conditions such as sleep quality, periodontitis, smoking, chronic inflammation and diseases, metabolic disorders and obesity, vascular dysfunction, and cancers would enable effective managemenet of COVID-19-associated complications in primary, secondary, and tertiary care in the context of predictive, preventive, and personalized medicine (3PM).

17.
Cureus ; 13(7): e16237, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34367834

ABSTRACT

Yellow nail syndrome is an extremely rare syndrome that presents with a clinical triad of thickened yellow nails, lymphedema, and recurring pulmonary manifestations (pleural effusion, chronic cough, or bronchiectasis), usually in the population above the age of 50 years. We describe a case of yellow nail syndrome in a 48-year-old lady who presented with the typical classical triad of this syndrome.

18.
Cureus ; 13(7): e16520, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34430131

ABSTRACT

Pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD) is associated with an increase in the risk of COPD exacerbation, increased hospitalization, and worse survival in this patient population. No specific treatment is available for PH in COPD. However, reported out-of-proportion PH may benefit from a certain type of treatment. This study shows that the use of selexipag in the treatment of out-of-proportion PH in COPD patients was associated with an improvement in functional status evaluated by a six-minute walk test (6MWT) and a mean pulmonary artery pressure at 6 +/- 2 months of treatment.

19.
Int J Mol Sci ; 22(16)2021 Aug 11.
Article in English | MEDLINE | ID: mdl-34445360

ABSTRACT

Multi-factorial mitochondrial damage exhibits a "vicious circle" that leads to a progression of mitochondrial dysfunction and multi-organ adverse effects. Mitochondrial impairments (mitochondriopathies) are associated with severe pathologies including but not restricted to cancers, cardiovascular diseases, and neurodegeneration. However, the type and level of cascading pathologies are highly individual. Consequently, patient stratification, risk assessment, and mitigating measures are instrumental for cost-effective individualized protection. Therefore, the paradigm shift from reactive to predictive, preventive, and personalized medicine (3PM) is unavoidable in advanced healthcare. Flavonoids demonstrate evident antioxidant and scavenging activity are of great therapeutic utility against mitochondrial damage and cascading pathologies. In the context of 3PM, this review focuses on preclinical and clinical research data evaluating the efficacy of flavonoids as a potent protector against mitochondriopathies and associated pathologies.


Subject(s)
Flavonoids/therapeutic use , Mitochondrial Diseases/diagnosis , Mitochondrial Diseases/prevention & control , Antioxidants/pharmacology , Antioxidants/therapeutic use , Cytoprotection/drug effects , Flavonoids/pharmacology , Humans , Mitochondria/drug effects , Mitochondria/metabolism , Mitophagy/drug effects , Oxidative Stress/drug effects , Precision Medicine/methods , Prognosis
20.
Cureus ; 13(5): e15360, 2021 May.
Article in English | MEDLINE | ID: mdl-34239792

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to anti-inflammatory therapies and the prognosis remains poor. In this review of literature, we will be focusing on main lines of treatment including current medications, supportive care, lung transplantation evaluation, and potential future strategies of treatment.

SELECTION OF CITATIONS
SEARCH DETAIL
...